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Abstract[ 
Acelylcodeine (ACOD) is a synthesis byproduct present in street 
heroin but not in pharmaceutical diacetylmorphine (DAM) as used 
in the Swiss program Heroin-Assisted Treatment for Opiate 
Dependent Drug Users (HAT). ACOD was evaluated and validated 
as an urine marker to detect he consumption of street heroin by 
HAT parlicipants. A gas chromatography-mass spectrometry 
method allowing the quantitation of ACOD concentrations as low 
as 0.2 ng/mL urine has been developed. In opiate-na'fve subjects, 
intravenous (i.v.) ACOD showed a plasma elimination half-life of 
237 • 18 rain, urine peak concentrations 2 h after administration, 
and a delection window of 8 h. Only 0.4 • 0.1% was excreted 
unchanged, with codeine (COD) as the main metabolite. ACOD 
may be formed by transacetylation when i.v. DAM and oral 
codeine are co-adminlstered. Toavoid false-positive results, the 
calculation of COD/ACOD ratios is recommended. In a study with 
105 HAT participants, 14% of the tested urines were ACOD 
positive. Only a low correlation was found between the 
anonymously self-declared consumption of street heroin and the 
ACOD positive rate. 
Introduction 
Between 1994 and 1996 the Swiss Federal Office of Public 
Health (SFOPH) conducted a research and feasibility study 
consisting of the dispensation of diacetylmorphine (DAM, 
heroin), morphine, and methadone to1035 heavy opiate de- 
pendents in 15 Swiss cities (1,2). Since 1999, this project has 
been running under the name Heroin-Assisted Treatment for 
Dependent Drug Users (HAT). Under strictly medicinally con- 
trolled conditions, single intravenous (i.v.) and oral doses of 
50-200 mg (up to 1000 mglday) of pharmaceutically pure DAM 
are administered to about 900 therapy-resistant heroin depen- 
dents. It is one of the primary goals of HAT to continously re- 
duce the DAM dose, ideally to zero. However, some heroin 
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dependents complain about insufficient doses a d claim that 
street heroin is, for whatever reason, more pharmacologically 
efficient. This motivates them to visit the street heroin market, 
which increases the not tolerated consumption of illegal street 
heroin. Therefore, the frequency of visits of the street heroin 
market and the consumption fillegal street heroin are among 
several quality parameters for checking the efficiency of the 
HAT programs. 
The analysis of 170 heroin specimens collected between 1991 
and 1996 in the street heroin market of Bern revealed th  pres- 
ence of acetylcodeine (ACOD) in more than 95% of the samples 
(3,4). The concentration f this impurity of manufacture, 
formed uring the acetylation process, varied between i and 
about 5%. In heroin samples confiscated in Switzerland be- 
tween 1991 and 1999, ACOD was detected in allof the 3489 an- 
alyzed samples (5). The ACOD concentration i  illicit heroin 
may reach up to 45% relative to DAM (6). 'I~o studies per- 
formed in the United States (7) and in Switzerland (8) showed 
the presence of ACOD in 37 and 86% of urines from street 
heroin users, espectively. Onthe other hand, ACOD was not de- 
tected in the pharmaceutical DAM used in HAT or in urine 
specimens from HAT participants who had received pharma- 
ceutical DAM under strictly controlled clinical conditions and 
had not consumed street heroin during treatment (8,9). ACOD 
was therefore evaluated as a potential urine marker to reveal re- 
cent concurrent use of pharmaceutical DAM and street heroin. 
In the first study ("pilot study"), 34%of urine specimens col- 
lected unannounced and on the same day from randomly se- 
lected HAT participants (n = 80)tested positive for ACOD (10). 
ACOD as a biornarker for long-term consumption of street 
heroin was also tested inhair obtained from HAT participants 
and from subjects who had ied from fatal opiate overdoses 
(11). Whereas ACOD was detected in 44% of the samples from 
the intoxication cases, none of the HAT specimens contained 
this marker. However, Staub et ai. (12) recently found ACOD in 
12% of hair samples from another population of HAT partici- 
pants. 
It was the aim of the present study to investigate he phar- 
macokinetics of i.v. administered ACOD in healthy volunteers, 
the possible formation f ACOD artifacts, and the feasibility 
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and reliability of an ACOD urine monitoring todifferentiate the 
use of street heroin and "state" heroin. For that purpose, urine 
specimens collected randomly and unannounced from HAT 
participants inseveral Swiss cities were analyzed by gas chro- 
matography-mass spectrometry (GC-MS). 
Experimental 
Materials 
ACOD hydrochloride (purity: 96.5%) and ACOD-d3 hy- 
drochloride (purity: 94.8%) were synthesized in our labora- 
tory (now also available through Lipomed, Arlesheim, 
Switzerland). Codeine (COD)-d3 was supplied byLipomed. COD 
phosphate was purchased from Merck, and COD phosphate 
tablets (50 mg) were obtained from Knoll (Liestal, Switzer- 
land). Isolute HCX 300 mg/3 mL solid-phase extraction (SPE) 
cartridges (International Sorbent Technology, Mid-Glamorgan, 
U.K.) were provided by ict AG (Basel, Switzerland). The Front- 
line | immunoassay (Boehringer Mannheim, Mannheim, Ger- 
many) used to screen for cocaine was purchased from Roche 
Diagnostics Corp. Switzerland. All chemicals were of analytical 
grade. 
Methods 
Subjects and clinical studies. Ten healthy, opiate-na'fve 
volunteers (5 male, 5 female; mean age 29.1 years) participated 
in the pharmacokinetic study, conducted at the Clinical 
Investigation Unit (CIU) of the University Hospital of Bern. 
The subjects were informed about he risks of the study and 
gave their written informed consent. The study has been 
approved by the Ethics Committee ofthe Faculty of Medicine, 
University of Bern. Each subject received 5 mg ACOD as a 
single i.v. bolus dose. Total urine specimens were collected 
10 rain before and 2, 4, 8, 12, 24, and 48 h after administration 
and stored at -20~ until analysis. Blood (5-10 mL) was 
Table I. Plasma Levels of ACOD in Opiate-Naive Subjects (n = 10) after an 
i.v. Bolus of 5 mg ACOD 
Time (min) 
Subject 0 5 10 20 40 60 120 240 480 
ACOD concentration (ng/mL) 
A 0 2681 640.8 210.3 92,7 51.3 45.3 15.8 
B 0 4226 684.8 324.9 170,3 64.6 32.3 26.4 
C 0 2014 104.9 20.2 8,0 3.6 0.5 0.7 
D 0 1222 285.9 112.1 63.1 50.8 15,1 9,0 
E 0 3540 295.0 68,5 111.9 38.0 15.5 9,0 
F 0 966.2 176.0 89.9 55.1 40.4 18.5 8.7 
G 0 1264 240.5 328.8 74.6 25.5 16.7 7.9 
H 0 2593 247.0 216.6 71.5 43,2 25.3 17.1 
t 0 800.4 403.8 109.7 104.9 47.2 20.1 5.6 
K 0 1311 217.5 119.1 54.5 20.0 22.9 12.1 
Mean 0 2062 329.6 160.0 80.7 38.5 21.2 11.2 
SEM 0 368.7 60.8 33.5 13.7 5.6 3.7 2.3 
collected through aperipheral vein catheter 5 min before and 
5, 10, 20, 40, 60, 120, 240, 480, and 720 rain after dosing. 
The heparinized blood samples were centrifuged for 10 min 
at 2000 rpm, and the plasma was instantly deep-frozen and 
stored at -20~ 
To check for a possible formation (transacetylation) of ACOD 
when co-administering COD and DAM, a 50-rag COD tablet was 
given to 10 HAT participants (informed consent, protocol ap- 
proved by the local Ethics Committee) 30 rain prior to an i.v. 
dose of 120--400 mg DAM (individually given by the HAT pro- 
tocol). Urine specimens were collected 10 rain before and 2, 4, 
and 8 h after DAM administration. 
For the feasibility study ("field study"), urine specimens from 
105 HAT participants in the cities of Bern, Thun, and Basel were 
collected randomly and unannounced on several days in July 
and August 2000, between 7 a d 9a.m. or 4and 7 p.m. 
Sample extraction. The extraction of ACOD, ACOD-d3, and 
COD from urine was performed by adding 10 mL of 0.03M 
phosphate buffer (pH 7.0) and 5 IJL of the internal standard so- 
lution (corresponding to 50 ng ACOD-d3) to a 10-mL aliquot of 
the centrifuged urine sample. After brief shaking, the sample 
was transferred onto the SPE column, preconditioned with 3 
mL of methanol and 3 mL of water, and drawn slowly through 
the column (1-2 mL/min, slight vacuum, without drying out). 
Six milliliters of water, 6 mL of 0.1M acetate buffer and 6 mL of 
methanol were used for washing (1-2 mL/rnin, slight vacuum, 
without drying out). After eluting with 4 mL dichloromethane/ 
2-propanol/ammonia (80:20:2, v/v) and drying under vacuum, 
the eluate was evaporated under nitrogen, the residue recon- 
stituted in 80 tJL of isooctane by sonication for 5 min, and 3 !JL 
used for GC-MS analysis. 
The extraction fACOD, ACOD-d3, and COD from plasma was 
performed by adding 1 mL of 0.03M phosphate buffer (pH 7.0) 
and 5 IJL of the internal standard solution to a 1-mL aliquot of 
the centrifuged plasma sample. The SPE procedure was the 
same as used for u ine extraction. 
GC-MS analysis. The quantitation ofACOD, ACOD-d3, and 
COD in urine and plasma was performed on a 
GC-MS system consisting of an HP 5890A se- 
ries II GC with electronic pressure control, an 
HP 7673A autosampler, an HP 5972 mass se- 
lective detector (MSD) operated inthe selected 
ion monitoring (SIM) mode, and HP 5895A 
720 Chemstation software. Chromatographic sep- 
aration was achieved ona J&W Scientific DB- 
8.4 8.0 5 MS capillary column (25 m x 0.2-mm i.d., 
21.9 3.8 0.33-t~m film thickness) and helium at 20.4 
o.5 o.7 cm/s as carrier gas. The oven temperature was 
5.8 4.9 initially held I rain at 180~ then increased to
5.8 4.7 280~ at a rate of 10~ and held at 280~ 
5.7 2.5 for 14 min. The injector and transfer line tern- 
6.6 4.3 peratures were 260 and 280~ respectively. 
6.1 o.5 The injector was operated in the splitless 
5.5 4.2 mode. 
5.7 5.5 Peak assignment of ACOD was achieved by
7.2 3.9 comparison ofthe retention time and the rel- 
1.8 o.7 ative abundance of the three characteristic 
ions m/z 341,282, 229 with the deuterated in- 
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ternal standard ACOD-d3 (m/z 344, 285, 232). COD was identi- 
fied by the ions m/z 162, 229, 299. Quantitation of ACOD and 
COD was based on the peak area ofthe ion rn/z 341 and 299, re- 
spectively, versus the peak area of the ACOD-d3 ion m/z 344. 
Calibration was performed inthe range of 0.25 to 25 ("low") and 
25 to 250 ng ("high") ACOD and COD per milliliter urine and 
plasma. 
Pharmacokinetic data analysis. Based on the noncompart- 
mental model, all pharmacokinetic parameters were assessed 
by use of standard calculation procedures p rformed by the 
Topfit (version 2.0) computer software (13). The linear trape- 
zoidal rule was implemented for calculations ofareas under 
the plasma concentration-time curves (AUC). The AUCs were 
extrapolated to infinity (AUC0-~ oo) by adding the last quanti- 
tated concentration (at 720 rain) divided by the elimination 
constant (~). 
Results and Discussion 
Method 
The SPE procedure showed ACOD and COD recoveries from 
urine and plasma in the range of 84 to 92%, determined at the 
1- and 25-ng/mL concentration levels (CV 4-6%, n = 4). Two 
calibration graphs were established tocover the broad range of 
analyte concentrations. The "low" calibration graph (0.25-25 
ng/mL ACOD and COD) was used when the peak-area ratio of 
ACOD and COD versus ACOD-d3 was _< 5.50 and _< 7.39, re- 
spectively. The "high" calibration graph (25-100 ng/mL ACOD, 
25-250 ng/mL COD) was used, when the ratio was ~ 5.51 and 
~o 100 
8 
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Figure 1. ACOD plasma profile after an i.v. bolus of 5 mg ACOD, opiate- 
ha'i've subjects (mean + SEM, n = 10). 
Table II. Pharmacokinetics of ACOD in Opiate-Na'fve Subjects (n = 10) after 
an i.v. Bolus of 5 mg ACOD 
Subject 
A B C D E F G H I K Mean SEM 
Gender f m m f m m f m f f 
t,,2z(min) 232 193 311 238 25,4 225 284 110 221 300 237 
Vz(L) 44 27 185 86 58 102 92 28 86 105 81 
CLtot 
(mL/min) 132 97 411 252 159 314 224 177 268 244 228 
>_ 7.40, respectively. Correlation coefficients (r) b tween 0.995 
and 0.999 indicate good linearity between analyte concentra- 
tions and corresponding MS detector response for both cali- 
bration ranges. The interday precision (CV, n = 5) of the ACOD 
and COD quantitation was between 6 and 15% at the 25 and 
0.25-ng/mL concentration level, respectively. With a signal-to- 
noise ratio f 6:1, the limit of quantitation (LOQ) in urine and 
plasma was 0.20 ng/mL ACOD and COD, whereas the limit of 
etection (LOD) was 0.10 ng/mL. The internal standard ACOD- 
d3 contained about 1% of undeuterated ACOD. In order to 
avoid false-positive results, this fact was taken in account when 
determing the LOQ of ACOD. No significant loss of ACOD by in 
vitro desacetylation t  COD could be observed in blood and 
urine specimens within at least 6 months when instantly deep- 
frozen after sampling and stored at -20~ 
Pharmacokinetics ofACOD 
After i.v. administration (bolus) of 5 mg ACOD to opiate- 
na'fve subjects ACOD plasma peaks (Cmax) of S00 to 4226 ng/mL 
(mean + SEM: 2062 + 369 ng/mL) occurred after 5 rain (Table 
I and Figure 1). The plasma elimination half-life (tv2z) was 110 
to 311 rain (237 • 18 rain), the volume of distribution (Vz) 27 
to 185 L (81 • 15 L), and the total clearance (CLtot) 97 to 314 
mL/min (228 • 29 mL/min). The pharmacokinetics of i.v. ACOD 
are summarized in Table II. All subjects excreted hehighest 
ACOD concentrations i  the 2-h urine (Table III). Peak ACOD 
concentrations varied between 4.9 and 471.9 ng/mL (mean 
98.7 + 44.2 ng/mL). In the 4-h urine, the ACOD ranged from 0.1 
to 11.6 ng/mL (2.9 • 1.3 ng/mL). The total amount of ACOD ex- 
creted with urine within 48 h was 2.7 to 61.5 IJg (19.3 • 5.7 IJg), 
corresponding to only 0.1 to 1.2% (0.4 • 0.1%) of the dose ad- 
ministered. Eight hours after administration the ACOD levels 
were below the LOQ. COD was the main urinary metabolite of 
ACOD (COD conjugates were not determined). With 566.9 to 
8351.3 ng/mL, the highest concentrations of COD were also 
measured in the 2-h urines (1716.6 • 798.5 ng/mL) demon- 
strating the rapid desacetylation of ACOD. The COD/ACOD 
ratios varied from I to 1704 (191 • 168, 2-h urine) and 45 to 
3614 (480 • 343, 4-h urine), respectively. 
Formation of ACOD by transacetylation of COD 
A controlled clinical study with HAT participants revealed, 
that ACOD is formed when high i.v. doses of DAM (120-400 mg) 
and oral COD (50 rag, e.g., as cough medication) are adminis- 
tered simultaneously (Table IV). ACOD concentrations ranged 
from 0 to 147.0 ng/mL, with mean peak con- 
centrations of 33.6 • 15 ng/mL in the 2-h 
urine samples. ACOD was also formed in the 
GC-MS after injection of an urine extract 
spiked with 1.5 I~g and 5 IJg/mL DAM and 
COD, respectively. As only 0.1% of a DAM dose 
is excreted unchanged in urine (14) this ACOD 
artifact formation observed after using a very 
18 high DAM concentration might not be relevant 
15 when analyzing real urine samples. The COD 
levels, resulting from COD ingestion and 
29 ACOD metabolism, varied between 0 and 
32,600 ng/mL, with mean peak concentrations 
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of 8882 • 3320 ng/mL in the 2-h urines (Table IV). In order to 
avoid false-positive ACOD results consecutively leading to un- 
justified assumption ofstreet heroin consumption, we recom- 
mend quantitation ofboth ACOD and COD and calculation of 
the COD/ACOD ratio. Mean COD/ACOD ratios of 874 • 285 (2- 
h urine), 4245 • 1632 (4-h urine) and 2509 • 2053 (8-h urine) 
resulted from the DAM-COD co-administration experiments, 
whereas the ratios from the pharmacokinetic (Table lII) and the 
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field study varied from 0 to 3614 (178 • 181) and from 0 to 47 
(2 _-!- 2), respectively. 
Feasibility studies with HAT program participants 
During the summer of the year 2000, a total of 105 urine 
specimens were collected at HAT centers located in three 
different cities in Switzerland ("field study"). Basing on the 
data of the pharmacokinetic and the transacetylation study, 
Table III. ACOD and COD Urine Levels and COD/ACOD 
Ratios in Opiate-Naive Subjects (n = 10) after an i.v. 
Bolus of 5 mg ACOD 
Time (11) 
Subject 0 2 4 8 12 24 48 
ACOD Concentration (ng/mt) 
A 0 471.9 0.8 0 0 0 0 
B 0 86.8 11.6 0 0 0 0 
C 0 169.1 6.8 0 0 0 0 
D 0 4.9 0.2 0 0 0 0 
E 0 22.2 0.5 0 0 0 0 
F 0 69.9 0.5 0 0 0 0 
G 0 13.8 0.1 0 0 0 0 
H 0 19.7 6.9 0 0 0 0 
I 0 65.6 0.9 0 0 0 0 
K 0 63.5 0.6 0 0 0 0 
Mean 0 98.7 2.9 0 0 0 0 
SEM 0 44.2 1.3 0 0 0 0 
COD Concentration (ng/mt) 
A 0 597.5 451.8 60.0 51.0 91.7 6.6 
B 0 673,t 562.8  140.0 n.a. 29.2 2.3 
C 0 3720 316.8 38.8 68.5 82.7 5.3 
D 0 8351 348.8 60.6 54.8 82.7 15.2 
E 0 714.0 333.0 52.3 53.2 74.4 4.9 
F 0 579.4 387.8 58.0 43.6 82.4 10.7 
G 0 655.9 361.4 58.3 46.2 75.2 5.1 
H 0 566.9 306.9 49.0 51.6 69.7 4.2 
I 0 585.5 440.4 75.8 47.7 70.3 5.9 
K 0 722.1 479.7 68.3 61.6 101.0 5.7 
Mean 0 1717 398.9 66.1 53.1 75.9 6.6 
SEM 0 798.5 26.1 8.8 2.5 6.0 1.2 
COD/ACOD-Ratio 
A 0 1 565 0 0 0 0 
B 0 8 49 0 0 0 0 
C 0 22 47 0 0 0 0 
D 0 1704 1744 0 0 0 0 
E 0 32 666 0 0 0 0 
F 0 83 776 0 0 0 0 
G 0 9 3614 0 0 0 0 
H 0 29 45 0 0 0 0 
I 0 9 489 0 0 0 0 
K 0 11 800 0 0 0 0 
Mean 0 191 480 0 0 0 0 
SEM 0 168 343 0 0 0 0 
Table IV. ACOD and COD Urine Levels and COD/ACOD 
Ratios after the Co-administration of 120 to 400 mg DAM 
i.v. and 50 mg COD p.o. to HAT Participants (n = 10) 
Time (h) 
Subject 0 2 4 8 
ACOD Concentration (ng/mL) 
A 0 2.1 0.2 0 
B 0 5.4 0.4 2.1 
C 0 10.7 0.8 0.1 
D 0 2.3 0 0 
E 0 4.3 3.2 0 
F 0 30.6 1.2 0 
G 0 62.8 1.6 0 
H 0 69.6 0.8 0 
I 0 1.5 33.7 7.0 
K 0 147.0 3.6 5.0 
Mean 0 33.6 4.6 1.4 
SEM 0 15.0 3.3 0.8 
COD Concentration (ng/mL) 
A 0 2198 1039 552.1 
B 0 6785 5804 7678 
C 0 6018 1667 2106 
D 0 1142 191.0 109.2 
E 0 3806 2256 109.5 
F 0 23,554 9225 4826 
G 0 2189 911.0 334.4 
H 0 32,600 8666 4359 
I 0 4765 1799 1646 
K 0 5760 2911 688.3 
Mean 0 8882 3447 2241 
SEM 0 3320 1036 810 
COD/ACOD.Ratio 
A 0 1047 5195 0 
B 0 1256 14,510 3656 
C 0 562 2084 21,060 
D 0 497 0 0 
E 0 885 705 0 
F 0 770 7688 0 
G 0 35 569 0 
H 0 468 10,833 0 
l 0 3177 53 235 
K 0 39 809 138 
Mean 0 
SEM 0 
874 4245 2509 
285 1632 2053 
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samples with ACOD levels > LOQ and COD/ACOD-ratios > 0 
and < 50 were considered as positive in respect of the use of 
street heroin in the last 24 h. In consequence, 15(14%) 
samples were positive, containing 0.3 to 103 ng/mL ACOD 
(22.1 • 9.4 ng/mL) and 0.5 to 3309 ng/mL COD (553.3 + 295.3 
ng/mL), respectively (Table V). The COD/ACOD ratios ranged 
from 0.4 to 47 (15 • 5). Only traces (< LOQ) of ACOD could be 
detected in20 samples (19%) with traces to 160 ng/mL of COD. 
These urines were regarded as negative. It is noteworthy that 
none of the subjects reported a COD medication i  the past 48 
h, meaning that ACOD formation by transacetylation is not
very likely. No ACOD-positive urines resulted from another 
study with 44 HAT participants (8). We assume that this dis- 
crepancy could bedue to other collection conditions (time, 
site etc.), differences in the HAT programs (other DAM dosage 
schemes, better psychosocial and medical care), more strictly 
enforced heroin street market and/or the less sensitive analyt- 
ical method used (LOQ I ng/mL) in the study of Staub et al. (8). 
It has to be mentioned that 30% of the ACOD-positive urines 
from our feasibility field study were in the concentration range 
> LOQ and < 1 ng/mL. 
The concomitant use of DAM and cocaine [e.g., by injection 
of a mixture of both drugs ("speedball")] is still popular in 
Switzerland. Whereas 81% of HAT participants declared daily 
heroin consumption before ntering the programs, 25% also re- 
ported aily cocaine use (1). Consequently, o check for a pos- 
sible correlation between the simultaneous presence of ACOD 
and cocaine in urine, all samples were analyzed by a non-in- 
strumental immunoassay (Frontline). Thirty percent of all 
urines tested positive for cocaine, nd 67% of the ACOD-posi- 
tive urines were also cocaine positive (Table V). To validate the 
Table V. Street Heroin Consumption by HAT Participants 
(n = 105, feasibility study) Detected by ACOD Urine 
Marker and Self-Report 
Concenlration (ng/mt) COD/ACOD Self. 
Sample ACOD COD Ratio Cocaine Report* 
I 31.9 760.1 24 pos yes 
2 0.5 0.6 I neg no 
3 0.3 1.3 4 pos no 
4 0.7 5.3 8 neg no 
5 11.5 181.3 16 pos yes 
6 20.0 435.5 22 pos yes 
7 0.4 0.5 1 neg no 
8 49.4 2000 40 neg yes 
9 20.3 235.7 12 pos yes 
I0 0.5 1.2 2 pos yes 
11 1.5 0.6 0.4 neg no 
12 10.7 502.8 47 pos yes 
13 66.5 861.0 13 pos yes 
14 103.3 3309 32 pos no 
15 13.6 5.3 0.4 pos no 
Mean 22.1 553.3 15 
SEM 9.4 295.3 5 
* Street heroin consumption i  the last 72 h reported confidentially by the HAT 
participants. 
self-declaration as a suitable nstrument for monitoring street 
heroin consumption, all participating subjects were asked to 
frankly report heir heroin and cocaine consumption utside 
HAT centers in the last 24 to 72 h. Although the self-reporting 
of drug use by face-to-face interview (standardized question- 
naire) was performed un er confidental conditions and, also in 
case of ACOD-positive t sting, without any consequences for 
the HAT participants, the concordance ofpositive results based 
on self-reporting and ACOD monitoring was unexpectedly 
rather low (53%). It has to be noted that under-reporting of 
drug use is a well-known phenomenon (15). No significant 
correlation was found between the day, time, and place of 
sample collection and the ACOD positives. 
Recently, Bogusz et al. (16) proposed the use, in addition to 
ACOD, of the native opium alkaloids noscapine a d papaverine 
for the differentiation of prescribed and non-prescription 
heroin. As these compounds are, at least in Switzerland, con- 
stituents of a few medicaments, interferences may not be ex- 
cluded. On the other hand, the simultaneous presence of all 
three compounds in urine could provide a strong evidence for 
street heroin consumption. Therefore, 15 ACOD-positive urines 
from the "field study" were randomly selected and reanalyzed by
GC-MS for the presence of noscapine and papaverine. Eight 
urines contained besides ACOD 0.1-183 ng/mL noscapine and 
0.1-I.9 ng/mL papaverine, respectively. One specimen con- 
tained ACOD and noscapine, and six contained ACOD only. A 
peak concentration f 6 ng/mL noscapine was measured in the 
urine of a patient who ingested 30 mg noscapine hydrochloride 
as a cough medication. After about 30 h, the detectability was 
much longer than that ofACOD. It has to be noted that he de- 
scribed GC-MS method for the determination f ACOD must be 
slightly modified for the simultaneous detection of ACOD, 
noscapine, and papaverine. 
Conclusions 
A pharmacokinetic study on opiate-na'fve subjects with a low 
i.v. dose of ACOD has revealed its rapid metabolism by des- 
acetylation and elimination from the body. Only a small fraction 
(0.4 + 0.1%) of the dose was recovered unchanged in urine, re- 
sulting in a rather narrow urine detection window. ACOD is also 
formed by in vivo transacetylation of simultaneously ingested 
COD and during GC-MS analysis when coinjecting high con- 
centrations of DAM and COD in a urine matrix. Despite these 
limitations we think that ACOD may be used in HAT programs 
as a socio-medical quality control tool for the detection of re- 
cent street heroin consumption, r vided that COD/ACOD-ra- 
tios are calculated o avoid false-positive results. The inclusion 
of other street heroin constituents (noscapine, papaverine) 
could increase the reliability ofthe ACOD monitoring, for ex- 
ample when used for forensic purposes, but more pharma- 
cokinetic and field studies that include heroin users outside 
HAT programs, are necessary. As there was a certain correlation 
between the simultaneous presence of ACOD and cocaine in 
urine, cocaine-positive r sults can be considered as an addi- 
tional hint for street heroin/cocaine ("speedballs") consump- 
565 
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tion. It seems, that even when performed confid ntially, the self- 
reporting is not much suited as monitoring instrument for 
street heroin consumption. 
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